metastatic/advanced - esophageal cancer (mEC) | |||
mEC - (neo)adjuvant (NA) | mEC - 1st line (L1) | mEC - 2nd line (L2) | |
anti-PD-(L)1 | |||
camrelizumab based treatment | |||
camrelizumab alone | |||
nivolumab based treatment | |||
nivolumab alone | CheckMate 577 | ||
pembrolizumab based treatment | |||
pembrolizumab alone | |||
pembrolizumab plus SoC |